Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.22
CYAN's Cash-to-Debt is ranked lower than
93% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CYAN: 0.22 )
Ranked among companies with meaningful Cash-to-Debt only.
CYAN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.63 Max: No Debt
Current: 0.22
Equity-to-Asset 0.57
CYAN's Equity-to-Asset is ranked lower than
62% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CYAN: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
CYAN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.39  Med: 0.76 Max: 0.92
Current: 0.57
-0.39
0.92
Piotroski F-Score: 4
Altman Z-Score: 1.55
Beneish M-Score: -3.99
WACC vs ROIC
10.01%
-16.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -3.89
CYAN's Operating Margin % is ranked higher than
69% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CYAN: -3.89 )
Ranked among companies with meaningful Operating Margin % only.
CYAN' s Operating Margin % Range Over the Past 10 Years
Min: -75.43  Med: 4.13 Max: 11.79
Current: -3.89
-75.43
11.79
Net Margin % -15.14
CYAN's Net Margin % is ranked higher than
64% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CYAN: -15.14 )
Ranked among companies with meaningful Net Margin % only.
CYAN' s Net Margin % Range Over the Past 10 Years
Min: -76.68  Med: 4.06 Max: 15.16
Current: -15.14
-76.68
15.16
ROE % -27.46
CYAN's ROE % is ranked higher than
56% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CYAN: -27.46 )
Ranked among companies with meaningful ROE % only.
CYAN' s ROE % Range Over the Past 10 Years
Min: -66.15  Med: 8.02 Max: 27.54
Current: -27.46
-66.15
27.54
ROA % -15.87
CYAN's ROA % is ranked higher than
63% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CYAN: -15.87 )
Ranked among companies with meaningful ROA % only.
CYAN' s ROA % Range Over the Past 10 Years
Min: -54  Med: 5.52 Max: 22.08
Current: -15.87
-54
22.08
ROC (Joel Greenblatt) % -5.52
CYAN's ROC (Joel Greenblatt) % is ranked higher than
74% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CYAN: -5.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CYAN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -70.18  Med: 7.63 Max: 32.17
Current: -5.52
-70.18
32.17
3-Year Revenue Growth Rate 5.50
CYAN's 3-Year Revenue Growth Rate is ranked higher than
50% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CYAN: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CYAN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -15.2  Med: 7.05 Max: 99.1
Current: 5.5
-15.2
99.1
3-Year EBITDA Growth Rate -37.60
CYAN's 3-Year EBITDA Growth Rate is ranked lower than
87% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CYAN: -37.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CYAN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -37.6  Med: 11.25 Max: 129.6
Current: -37.6
-37.6
129.6
GuruFocus has detected 2 Warning Signs with Cyanotech Corp $CYAN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CYAN's 30-Y Financials

Financials (Next Earnings Date: 2017-06-23 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CYAN Guru Trades in Q2 2016

Jim Simons 96,300 sh (+2.99%)
» More
Q3 2016

CYAN Guru Trades in Q3 2016

Jim Simons 97,600 sh (+1.35%)
» More
Q4 2016

CYAN Guru Trades in Q4 2016

Jim Simons 100,900 sh (+3.38%)
» More
Q1 2017

CYAN Guru Trades in Q1 2017

Jim Simons 103,600 sh (+2.68%)
» More
» Details

Insider Trades

Latest Guru Trades with CYAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:PRGB, OTCPK:OBMP, NAS:PRTO, NAS:ABIO, OTCPK:PRTX, NAS:TRPX, NAS:CLRB, NAS:GALE, OTCPK:PRNAF, NAS:CYCC, OTCPK:BIVI, NAS:CAPR, OTCPK:PKTX, OTCPK:PTIX, NAS:HTBX, OTCPK:BRTX, NAS:APTO, OTCPK:NULF, NAS:ONTX, NAS:ONCS » details
Headquarter Location:USA
Cyanotech Corp cultivates and produces natural products derived from microalgae for the nutritional supplements market. The Company's products include Spirulina Pacifica and natural astaxanthin.

Cyanotech Corp was incorporated in 1983. The Company cultivates and produces natural products derived from microalgae for the nutritional supplements market. Its products include Hawaiian Spirulina Pacifica - a nutrient-rich dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids; and Hawaiian BioAstin natural astaxanthin - a powerful dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health. It has expanding applications as a human nutraceutical and functional food ingredient. The Spirulina Pacifica is produced in two forms powder and tablets, and BioAstin is produced in three forms a liquid lipid extract, and gelcaps. Its products are marketed and sold in bulk quantities to manufacturers, formulators and distributors in the health foods and nutritional supplements markets and as packaged consumer products to distributors, retailers and direct consumers. The Company' has four United States patents in force: one on aspects of its production methods and three for use of its BioAstin products. The Company's competitors include Dainippon Ink and Chemical Company's Earthrise facility in California, Parry Nutraceuticals, a division of Murugappa Group of India and several farms in China. Several governmental agencies regulate various aspects of the company's business and its products in the United States, including the Food and Drug Administration, the Federal Trade Commission, the Consumer Product Safety Commission, the State of Hawaii Department of Health, the Department of Agriculture, the Environmental Protection Agency, the United States Postal Service, state attorney general offices and various agencies of the states and localities in which the company's products are sold.

Ratios

vs
industry
vs
history
PB Ratio 1.21
CYAN's PB Ratio is ranked higher than
87% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CYAN: 1.21 )
Ranked among companies with meaningful PB Ratio only.
CYAN' s PB Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.4 Max: 3.68
Current: 1.21
0.63
3.68
PS Ratio 0.63
CYAN's PS Ratio is ranked higher than
97% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CYAN: 0.63 )
Ranked among companies with meaningful PS Ratio only.
CYAN' s PS Ratio Range Over the Past 10 Years
Min: 0.42  Med: 0.93 Max: 2.32
Current: 0.63
0.42
2.32
Price-to-Operating-Cash-Flow 39.25
CYAN's Price-to-Operating-Cash-Flow is ranked lower than
76% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. CYAN: 39.25 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CYAN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.45  Med: 13.72 Max: 61.45
Current: 39.25
4.45
61.45
EV-to-EBIT -20.77
CYAN's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CYAN: -20.77 )
Ranked among companies with meaningful EV-to-EBIT only.
CYAN' s EV-to-EBIT Range Over the Past 10 Years
Min: -398.9  Med: 7.9 Max: 178.7
Current: -20.77
-398.9
178.7
EV-to-EBITDA 39.84
CYAN's EV-to-EBITDA is ranked lower than
78% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CYAN: 39.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYAN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -102.1  Med: 10.2 Max: 98.8
Current: 39.84
-102.1
98.8
Current Ratio 2.02
CYAN's Current Ratio is ranked lower than
74% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CYAN: 2.02 )
Ranked among companies with meaningful Current Ratio only.
CYAN' s Current Ratio Range Over the Past 10 Years
Min: 0.3  Med: 2.72 Max: 8.33
Current: 2.02
0.3
8.33
Quick Ratio 0.79
CYAN's Quick Ratio is ranked lower than
88% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CYAN: 0.79 )
Ranked among companies with meaningful Quick Ratio only.
CYAN' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 1.63 Max: 7.93
Current: 0.79
0.1
7.93
Days Inventory 136.81
CYAN's Days Inventory is ranked lower than
52% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CYAN: 136.81 )
Ranked among companies with meaningful Days Inventory only.
CYAN' s Days Inventory Range Over the Past 10 Years
Min: 70.29  Med: 99.59 Max: 141.39
Current: 136.81
70.29
141.39
Days Sales Outstanding 27.30
CYAN's Days Sales Outstanding is ranked higher than
80% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CYAN: 27.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYAN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.3  Med: 47.28 Max: 62.12
Current: 27.3
27.3
62.12
Days Payable 62.67
CYAN's Days Payable is ranked higher than
52% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CYAN: 62.67 )
Ranked among companies with meaningful Days Payable only.
CYAN' s Days Payable Range Over the Past 10 Years
Min: 26.29  Med: 43.7 Max: 73.1
Current: 62.67
26.29
73.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.80
CYAN's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CYAN: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYAN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -30.5  Med: -4.6 Max: 31.8
Current: -0.8
-30.5
31.8

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.22
CYAN's Price-to-Tangible-Book is ranked higher than
90% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CYAN: 1.22 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CYAN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.5  Med: 1.55 Max: 15.83
Current: 1.22
0.5
15.83
Price-to-Intrinsic-Value-Projected-FCF 5.07
CYAN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
67% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. CYAN: 5.07 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CYAN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.75  Med: 2.02 Max: 165.52
Current: 5.07
0.75
165.52
Price-to-Median-PS-Value 0.67
CYAN's Price-to-Median-PS-Value is ranked higher than
71% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CYAN: 0.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CYAN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.49  Med: 1.7 Max: 16.72
Current: 0.67
0.49
16.72
Earnings Yield (Greenblatt) % -4.81
CYAN's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CYAN: -4.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CYAN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.92  Med: 7.6 Max: 18.2
Current: -4.81
-4.92
18.2
Forward Rate of Return (Yacktman) % 3.55
CYAN's Forward Rate of Return (Yacktman) % is ranked lower than
72% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. CYAN: 3.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CYAN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3  Med: 1.3 Max: 37.2
Current: 3.55
-3
37.2

More Statistics

Revenue (TTM) (Mil) $32.99
EPS (TTM) $ -0.89
Beta1.36
Short Percentage of Float0.24%
52-Week Range $3.32 - 5.56
Shares Outstanding (Mil)5.67

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}